Classic Review,Glucagon-like peptide-1 (GLP-1

The intricate balance of glucose metabolism within the human body is orchestrated by a complex interplay of hormones, among which glucagon and glucagon-like peptide-1 (GLP-1) play pivotal roles. While both are peptides derived from a common precursor, preproglucagon, their functions and impacts on blood sugar regulation are distinct, leading to varied therapeutic applications. Understanding the nuances of glucagon vs glucagon-like peptide-1 is crucial for comprehending their physiological significance and their implications in managing conditions like diabetes and obesity.

Glucagon, a hormone primarily produced by the alpha cells of the pancreas, acts as a counter-regulatory hormone to insulin. Its main function is to increase blood glucose levels when they drop too low (hypoglycemia). It achieves this through several mechanisms, including stimulating glycogenolysis (the breakdown of glycogen stored in the liver into glucose) and gluconeogenesis (the synthesis of glucose from non-carbohydrate sources in the liver). Essentially, glucagon signals the liver to release stored glucose into the bloodstream, thereby raising blood sugar.

In contrast, Glucagon-like peptide-1 (GLP-1) is an incretin hormone primarily secreted by the L-cells of the intestine in response to nutrient intake. GLP-1 is a 30- or 31-amino-acid-long peptide hormone that originates from the tissue-specific posttranslational processing of proglucagon. Its actions are largely glucose-dependent, meaning it exerts its effects most potently when blood glucose levels are elevated.

One of the most significant roles of GLP-1 is its ability to stimulate glucose-dependent insulin secretion from the beta cells of the pancreas. This means that GLP-1 enhances insulin release only when blood glucose is high, thereby helping to lower it without increasing the risk of hypoglycemia. Furthermore, GLP-1 has several other beneficial effects on glucose homeostasis. It suppresses glucagon secretion from pancreatic alpha cells, which, in turn, reduces the liver's production of glucose. This action directly counteracts the primary function of glucagon.

Beyond its direct impact on glucose metabolism, GLP-1 also plays a crucial role in appetite regulation and gastrointestinal function. It regulates appetite and food intake by slowing down gastric emptying, which leads to a feeling of fullness and satiety. This effect contributes to reduced food consumption and can be a significant factor in weight management. Research suggests that GLP-1 primarily affects appetite and blood sugar signals.

The glucagon-like peptide-1 receptor (GLP-1R) is a G protein-coupled receptor (GPCR) found on various cell types, including beta cells in the pancreas and neurons in the brain. Activation of the GLP-1 receptor mediates the diverse physiological effects of GLP-1. GLP-1R signaling suppresses the release of glucagon, a hormone that raises blood glucose levels by stimulating hepatic glucose production.

While glucagon and GLP-1 originate from the same precursor, their physiological roles diverge significantly. Glucagon is catabolic, increasing blood glucose, while GLP-1 is anabolic and hypoglycemic, promoting insulin secretion and reducing glucose production. The half-life of circulating biologically active GLP-1 is remarkably short, less than 2 minutes, necessitating rapid action or the development of more stable analogs. In contrast, glucagon has a longer circulating half-life.

The therapeutic potential of GLP-1 has led to the development of GLP-1 receptor agonists (GLP-1RAs). These medications are designed to mimic the effects of endogenous GLP-1 and are widely used in the management of type 2 diabetes, contributing to improved glycemic control. GLP-1R agonists work by mimicking the effects of glucagon-like peptide-1 (GLP-1). They have been shown to effectively reduce HbA1c levels in patients with type 2 diabetes. Furthermore, GLP-1 is an anti-diabetic medication and is also used for long-term weight management.

It is important to distinguish GLP-1 from other related peptides. For instance, Glucagon-like peptide-2 (GLP-2), while also derived from proglucagon, primarily focuses on supporting the gut and intestinal lining, with a half-life of approximately 5–7 minutes, making it more stable than GLP-1.

The distinct actions of GLP-1 and other incretin hormones like GIP (glucose-dependent insulinotropic polypeptide) are also noteworthy. While both GIP and GLP-1 are incretins, they have some differing effects. GIP has a more direct effect on fat metabolism, promoting lipid storage and fat accumulation, whereas GLP-1's primary actions are on glucose control and appetite. In fact, **GIP and GLP-1 have opposite effects on